These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35890180)

  • 61. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis.
    Nusbaum KB; Fleischer S; Fleischer AB
    J Dermatolog Treat; 2022 Aug; 33(5):2534-2544. PubMed ID: 34620047
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being.
    Rademaker M; Jarrett P; Murrell DF; Sinclair RD; Pasfield L; Poppelwell D; Shumack S
    Australas J Dermatol; 2024 Sep; 65(6):e145-e155. PubMed ID: 38773888
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.
    Canonica GW; Bourdin A; Peters AT; Desrosiers M; Bachert C; Weidinger S; Simpson EL; Daizadeh N; Chen Z; Kamat S; Khan AH; Chao J; Graham NMH; Laws E; Rossi AB; Ardeleanu M; Mannent LP; Amin N; Ortiz B; Deniz Y; Djandji M; Rowe PJ
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1515-1526. PubMed ID: 35259535
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dupilumab for treatment of atopic dermatitis.
    Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
    Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
    J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
    Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
    J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Is dupilumab effective in adult-onset atopic dermatitis: Real-life experience of 16 patients.
    Erbağcı E; Demirel Öğüt N; Koç Yıldırım S; Hapa FA
    J Cosmet Dermatol; 2022 Oct; 21(10):4852-4857. PubMed ID: 35100490
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
    Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
    Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dupilumab for the treatment of adult atopic dermatitis in special populations.
    Patruno C; Potestio L; Scalvenzi M; Battista T; Raia F; Picone V; Fabbrocini G; Napolitano M
    J Dermatolog Treat; 2022 Nov; 33(7):3028-3033. PubMed ID: 35829641
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).
    Bagel J; Nguyen TQ; Lima H; Jain N; Pariser DM; Hsu S; Yosipovitch G; Zhang H; Chao J; Bansal S; Chen Z; Richman D; Korotzer A; Ardeleanu M
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1417-1430. PubMed ID: 35590038
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis.
    de Bruin-Weller MS; Serra-Baldrich E; Barbarot S; Grond S; Schuster C; Petto H; Capron JP; Raibouaa A; Werfel T
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1481-1491. PubMed ID: 35543919
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acupuncture improves symptoms in patients with mild-to-moderate atopic dermatitis: A randomized, sham-controlled preliminary trial.
    Kang S; Kim YK; Yeom M; Lee H; Jang H; Park HJ; Kim K
    Complement Ther Med; 2018 Dec; 41():90-98. PubMed ID: 30477869
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis.
    Nettis E; Patella V; Lombardo C; Detoraki A; Macchia L; Di Leo E; Carbonara M; Canonica GW; Bonzano L
    Allergy; 2020 Oct; 75(10):2653-2661. PubMed ID: 32424957
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
    Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Napolitano M; Fabbrocini G; Potestio L; Fontanella G; Picone V; Bennardo L; Scalvenzi M; Patruno C
    Dermatol Ther; 2022 Aug; 35(8):e15588. PubMed ID: 35569129
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.